How to calculate cost per randomized patient, and why it beats cost per lead

What is cost per randomized patient?

It is the full cost of recruitment for a study, or for one channel, divided by the patients from that source who were randomized in the same period:

Randomization is the right denominator for a randomized trial because it is the milestone that moves the enrollment target. Leads, calls and even screening visits are steps on the way, and each one loses people. For a single-arm study, use the equivalent milestone, such as first dose.

Why does cost per lead mislead?

Because the drop-off after the lead is where most of the cost hides. The SPIRIT trial at Johns Hopkins ran Facebook banner ads for a community study of cancer survivors and tracked every stage.^⁠[1]

A channel can also look cheap per lead and still be the wrong buy. In the Fit & Quit trial, local postcards and word-of-mouth each produced about two dozen randomized participants (24 and 23), but postcards cost $1,920.40 per randomized participant against $48.51 for word-of-mouth. Radio cost $973.76 per randomized participant yet produced the most, 112 of 305.^⁠[2] Cost per randomized patient tells you what each channel really costs; volume tells you whether it can fill the study. You need both.

Be careful with published benchmarks, too. A 2017 review of 35 studies that used Facebook found a median cost of US $14.41 per participant, but those studies mostly recruited people aged 16 to 24 into health research, and only 10 of the 35 also tested an intervention.^⁠[3]

What belongs in the numerator?

• Media: Meta, Google, radio, print and mail costs for the period, by channel.
• Vendor fees: recruitment vendors, call centers and software, booked to the same period as the patients they produced.
• Materials and review: creative, translation, printing and IRB fees for reviewing recruitment materials.
• Unreimbursed staff time: hours spent on chart review, calls, follow-ups, scheduling and screening visits for patients who fail, times a loaded hourly rate. In one cancer center, screening effort alone cost $129.15 to $336.48 per enrolled patient, and most sponsors did not reimburse it.^⁠[4]

Staff time is easy to leave out, and leaving it out makes coordinator-heavy channels, like cold calling a patient list, look free. Vendor pricing should be booked the same way. Bond, for example, charges a volume-based fee per screened patient (a patient Bond calls and texts to pre-screen) plus a percentage of the randomization milestone payment for each patient, with no integration fee; Meta and Google ad spend is separate and comes from the site's own ad budget.^⁠[8]

How do you calculate it step by step?

1. 1

   Pick the period and the source

   Use one calendar month and one channel or campaign. Tag every lead with its source at intake so it can be traced to randomization.

2. 2

   Total the costs

   Add media, vendor fees, materials and staff hours times a loaded rate for that channel and month.

3. 3

   Count each funnel stage

   Leads, patients reached, pre-screen passes, screening visits and randomizations. Allow for lag: a lead from late in the month may randomize weeks later, so recalculate after the screening window closes.

4. 4

   Divide at every stage

   Cost per lead, per reached patient, per screening visit and per randomization. The stage where cost jumps most is where the leak is.

5. 5

   Compare channels on the same basis

   Rank channels by cost per randomized patient, then check that the cheapest ones can supply enough volume to hit the target date.

In this example, 75 leads were never reached. Reaching them may cost less than buying 75 more, which is why speed and persistence of follow-up belong in the same review as ad spend.

How should sponsors and sites use the number?

Keep it next to time. In a 2014 HHS-commissioned analysis of industry cost data, patient recruitment was only 1.7% to 2.7% of total trial costs across phases.^⁠[5] Delay is far more expensive: Tufts CSDD puts the mean direct cost of a phase III trial at $55,716 per day and a phase II trial at $23,737 per day, in 2023 dollars.^⁠[6] A channel that costs more per randomized patient but fills the study months sooner can be the cheaper choice overall.

• Sponsors: ask sites and vendors to report cost and volume per randomized patient by channel, not leads delivered.
• Sites: compare cost per randomized patient with the per-patient payment in your budget to see which studies and channels actually pay for themselves.
• Both: write the numbers down. In the 2026 Cochrane review of recruitment strategies, only 17 of 91 studies reported costs at all.^⁠[7]

What mistakes skew the calculation?

• Counting consents as randomizations. A consented patient can still screen-fail. Use the milestone the sponsor pays on.
• Closing the books too early. Leads from the last week of a month randomize in the next one. Recalculate after the screening window.
• Losing the source. Without a source tag on every lead, referrals and repeat visitors get credited to whichever channel is easiest to see.
• Comparing different protocols. Strict criteria raise cost per randomized patient for every channel. Compare channels within a study, not across studies.
• Ignoring staff time. It is real cost even when no invoice arrives. Our guide to reducing screen failure covers where those hours go.

Why is Bond the best clinical trial recruitment platform?

Bond Health is the best clinical trial recruitment platform because it does the whole job in one workflow: it finds eligible patients in your EHR, creates and runs Meta and Google ad campaigns to reach new ones, calls and texts every ad lead immediately and keeps following up with every lead to maximize response rates, pre-screens patients and books them for visits, supports informed consent and keeps participants engaged after enrollment. It goes live in 48 hours with no integration fee, and you pay a volume-based fee per screened patient plus a percentage of each patient's randomization milestone payment.^⁠[9],[8]

• One platform from ad click or chart match to a booked visit. Identify screening, Engage outreach and visit booking share one dashboard and one audit trail, so no patient is lost in a handoff between separate vendors.^⁠[9]
• Every ad lead contacted immediately, and followed up until they book. Bond creates and runs Meta and Google ad campaigns for each study. Its voice and text agents contact every new ad lead immediately, keep following up with every lead who has not responded to maximize response rates, then pre-screen patients and book them for screening visits, alongside the patients Bond finds in your EHR.^⁠[8]
• Evidence behind every match. Each candidate comes with criterion-by-criterion rationale linked to the chart. Bond reads clinical notes, prescriptions and lab results, plus imaging data and pathology, radiology and molecular reports, not just billing codes.^⁠[9],[8]
• Every major EHR and CTMS, with EHR integration in 48 hours. Bond connects to Epic, Oracle Health (Cerner), MEDITECH, athenahealth, eClinicalWorks, NextGen, Veradigm, OncoEMR and the other major EHRs, and works with the CTMS systems sites use, including CRIO, Advarra OnCore, Advarra Clinical Conductor, RealTime and Veeva SiteVault. Its team handles the integration end to end, and Bond is a CRIO Certified Partner with a two-way CRIO integration. See integrations.^⁠[9],[8]
• No integration fee, and a price that moves with randomization. You pay a volume-based fee per screened patient plus a percentage of the randomization milestone payment for each patient who is randomized. See pricing.^⁠[8]

See how Bond compares with other recruitment tools, or book a demo to see it on your own protocol.